Guiyu Lei, Siliu Yang, Lili Wu, Yue Yin, Chunhua Xi, Yang Xiao, Guyan Wang
{"title":"Improved Tubeless Airway Management in JORRP Surgery: Comparative Analysis of Pre- and Post-THRIVE Implementation.","authors":"Guiyu Lei, Siliu Yang, Lili Wu, Yue Yin, Chunhua Xi, Yang Xiao, Guyan Wang","doi":"10.2147/TCRM.S513941","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a severe pediatric condition requiring frequent surgical interventions to maintain airway patency. Managing oxygenation during tubeless anesthesia for these surgeries poses significant challenges. In 2021, our center introduced transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) as a novel method for airway management in JORRP surgeries. This study evaluated the impact of THRIVE on perioperative outcomes in pediatric JORRP surgeries.</p><p><strong>Methods: </strong>This was a retrospective study of 122 pediatric JORRP surgical cases carried out at a tertiary center. Patients who underwent surgery prior to the implementation of THRIVE served as the control group (pre-THRIVE), while those treated after its introduction served as the intervention group (post-THRIVE), with 61 patients in each group. Perioperative data, including surgery and anesthesia parameters and extubation frequency were collected.</p><p><strong>Results: </strong>A total of 122 patients were included. Baseline characteristics were comparable between groups. After the introduction of THRIVE, the median number of extubations significantly decreased from a median 3 in the pre-THRIVE group to 1 in the post-THRIVE group (<i>P</i> <0.001). Minimum intraoperative SpO<sub>2</sub> levels were significantly higher in the post-THRIVE group (98% vs 85%, <i>P</i> <0.001). Surgery duration was reduced from 41 minutes to 35.5 minutes (<i>P</i> =0.003), and anesthesia duration decreased from 67 minutes to 58.5 minutes (<i>P</i> =0.016). No significant differences were observed in PACU stay length or complications between the groups.</p><p><strong>Conclusion: </strong>The implementation of THRIVE in pediatric JORRP enhances intraoperative efficiency and safety. Further research is warranted to assess its long-term effect.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"647-654"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068389/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S513941","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a severe pediatric condition requiring frequent surgical interventions to maintain airway patency. Managing oxygenation during tubeless anesthesia for these surgeries poses significant challenges. In 2021, our center introduced transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) as a novel method for airway management in JORRP surgeries. This study evaluated the impact of THRIVE on perioperative outcomes in pediatric JORRP surgeries.
Methods: This was a retrospective study of 122 pediatric JORRP surgical cases carried out at a tertiary center. Patients who underwent surgery prior to the implementation of THRIVE served as the control group (pre-THRIVE), while those treated after its introduction served as the intervention group (post-THRIVE), with 61 patients in each group. Perioperative data, including surgery and anesthesia parameters and extubation frequency were collected.
Results: A total of 122 patients were included. Baseline characteristics were comparable between groups. After the introduction of THRIVE, the median number of extubations significantly decreased from a median 3 in the pre-THRIVE group to 1 in the post-THRIVE group (P <0.001). Minimum intraoperative SpO2 levels were significantly higher in the post-THRIVE group (98% vs 85%, P <0.001). Surgery duration was reduced from 41 minutes to 35.5 minutes (P =0.003), and anesthesia duration decreased from 67 minutes to 58.5 minutes (P =0.016). No significant differences were observed in PACU stay length or complications between the groups.
Conclusion: The implementation of THRIVE in pediatric JORRP enhances intraoperative efficiency and safety. Further research is warranted to assess its long-term effect.
背景:青少年复发性呼吸道乳头状瘤病(JORRP)是一种严重的儿童疾病,需要频繁的手术干预来维持气道通畅。在这些手术中,无管麻醉期间的氧合管理提出了重大挑战。2021年,我中心引入经鼻加湿快速充气通气交换(THRIVE)作为JORRP手术气道管理的新方法。本研究评估了THRIVE对小儿JORRP手术围手术期预后的影响。方法:回顾性分析某三级中心122例小儿JORRP手术病例。在实施THRIVE前接受手术的患者作为对照组(pre-THRIVE),而在实施THRIVE后接受治疗的患者作为干预组(post-THRIVE),每组61例患者。收集围手术期资料,包括手术和麻醉参数及拔管次数。结果:共纳入122例患者。各组间基线特征具有可比性。引入THRIVE后,拔管次数中位数从THRIVE前组的中位数3次显著降低到THRIVE后组的中位数1次(THRIVE后组的p2水平显著升高(98% vs 85%, P =0.003),麻醉时间从67分钟减少到58.5分钟(P =0.016)。两组间PACU住院时间及并发症无显著差异。结论:THRIVE在小儿JORRP手术中的应用提高了术中效率和安全性。需要进一步的研究来评估其长期效果。
期刊介绍:
Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.
The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.
As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.
The journal does not accept study protocols, animal-based or cell line-based studies.